Genovis AB (publ.)
The answer first
Does Genovis beat the market?
No, Genovis has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 52% of Nordic stocks
- Quality77
- Value9
- Trend74
No. 57 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Genovis keeps must grow about 10% a year for 10 years.
Max for seven days
Follow Genovis with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Genovis
Your first answer is free, no account needed.
Do you own Genovis, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Genovis and a few more. Free, no card.
Super Stock+44.6%In short
- Genovis has risen 12.5% over the past year, including dividends.
- Overall, Genovis ranks better than 52% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 77.0%. The price is 77.6% below its peak now.
What do analysts think of Genovis?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 52% of Nordic stocks.
No. 57 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 64 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.49
- Asset turnoverSales divided by everything the company owns0.34
- Return on equityProfit divided by equity+5.3%
- Cash conversionOperating cash flow divided by profit3.30
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 142 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity4.8
- P/SPrice divided by sales10.1
- P/EPrice divided by earnings89.9
- P/CFPrice divided by operating cash flow27.2
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 50 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+11.9%
- 6 months+9.5%
- 9 months+31.9%
- 12 months+12.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Genovis
6 funds we follow own Genovis. The share is how much of the fund the stock makes up.
- Norway1
- Sweden5
From the funds' latest known holdings.
About Genovis
Genovis AB (publ.) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 36 employees.
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues.


See the full analysis of Genovis.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card